134 related articles for article (PubMed ID: 11935218)
1. Preclinical study of dolastatin-10 in dogs with spontaneous neoplasia.
Thamm DH; MacEwen EG; Phillips BS; Hershey AE; Burgess KM; Pettit GR; Vail DM
Cancer Chemother Pharmacol; 2002 Mar; 49(3):251-5. PubMed ID: 11935218
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses.
Tamura K; Nakagawa K; Kurata T; Satoh T; Nogami T; Takeda K; Mitsuoka S; Yoshimura N; Kudoh S; Negoro S; Fukuoka M
Cancer Chemother Pharmacol; 2007 Jul; 60(2):285-93. PubMed ID: 17136542
[TBL] [Abstract][Full Text] [Related]
3. Systemic administration of an attenuated, tumor-targeting Salmonella typhimurium to dogs with spontaneous neoplasia: phase I evaluation.
Thamm DH; Kurzman ID; King I; Li Z; Sznol M; Dubielzig RR; Vail DM; MacEwen EG
Clin Cancer Res; 2005 Jul; 11(13):4827-34. PubMed ID: 16000580
[TBL] [Abstract][Full Text] [Related]
4. A phase I study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously daily for 5 consecutive days every 3 weeks in patients with advanced solid tumors.
Ebbinghaus S; Rubin E; Hersh E; Cranmer LD; Bonate PL; Fram RJ; Jekunen A; Weitman S; Hammond LA
Clin Cancer Res; 2005 Nov; 11(21):7807-16. PubMed ID: 16278403
[TBL] [Abstract][Full Text] [Related]
5. Toxicity of dolastatin 10 in mice, rats and dogs and its clinical relevance.
Mirsalis JC; Schindler-Horvat J; Hill JR; Tomaszewski JE; Donohue SJ; Tyson CA
Cancer Chemother Pharmacol; 1999; 44(5):395-402. PubMed ID: 10501913
[TBL] [Abstract][Full Text] [Related]
6. Preclinical investigation of PEGylated tumor necrosis factor alpha in dogs with spontaneous tumors: phase I evaluation.
Thamm DH; Kurzman ID; Clark MA; Ehrhart EJ; Kraft SL; Gustafson DL; Vail DM
Clin Cancer Res; 2010 Mar; 16(5):1498-508. PubMed ID: 20160058
[TBL] [Abstract][Full Text] [Related]
7. Preclinical evaluation of antiangiogenic thrombospondin-1 peptide mimetics, ABT-526 and ABT-510, in companion dogs with naturally occurring cancers.
Rusk A; McKeegan E; Haviv F; Majest S; Henkin J; Khanna C
Clin Cancer Res; 2006 Dec; 12(24):7444-55. PubMed ID: 17189418
[TBL] [Abstract][Full Text] [Related]
8. Phase I clinical and pharmacokinetic study of kahalalide F administered weekly as a 1-hour infusion to patients with advanced solid tumors.
Pardo B; Paz-Ares L; Tabernero J; Ciruelos E; García M; Salazar R; López A; Blanco M; Nieto A; Jimeno J; Izquierdo MA; Trigo JM
Clin Cancer Res; 2008 Feb; 14(4):1116-23. PubMed ID: 18281545
[TBL] [Abstract][Full Text] [Related]
9. Lomustine and prednisone as a first-line treatment for dogs with multicentric lymphoma: 17 cases (2004-2005).
Sauerbrey ML; Mullins MN; Bannink EO; Van Dorp TE; Kaneene JB; Obradovich JE
J Am Vet Med Assoc; 2007 Jun; 230(12):1866-9. PubMed ID: 17571992
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative, for the treatment of patients with non-small cell lung cancer.
Horti J; Juhasz E; Monostori Z; Maeda K; Eckhardt S; Bodrogi I
Cancer Chemother Pharmacol; 2008 Jun; 62(1):173-80. PubMed ID: 18214483
[TBL] [Abstract][Full Text] [Related]
11. Phase I and pharmacokinetic study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously on days 1, 3, and 5 every 3 weeks in patients with advanced solid tumors.
Cunningham C; Appleman LJ; Kirvan-Visovatti M; Ryan DP; Regan E; Vukelja S; Bonate PL; Ruvuna F; Fram RJ; Jekunen A; Weitman S; Hammond LA; Eder JP
Clin Cancer Res; 2005 Nov; 11(21):7825-33. PubMed ID: 16278405
[TBL] [Abstract][Full Text] [Related]
12. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies.
London CA; Hannah AL; Zadovoskaya R; Chien MB; Kollias-Baker C; Rosenberg M; Downing S; Post G; Boucher J; Shenoy N; Mendel DB; McMahon G; Cherrington JM
Clin Cancer Res; 2003 Jul; 9(7):2755-68. PubMed ID: 12855656
[TBL] [Abstract][Full Text] [Related]
13. Phase I and pharmacokinetic study of the dolastatin 10 analogue TZT-1027, given on days 1 and 8 of a 3-week cycle in patients with advanced solid tumors.
de Jonge MJ; van der Gaast A; Planting AS; van Doorn L; Lems A; Boot I; Wanders J; Satomi M; Verweij J
Clin Cancer Res; 2005 May; 11(10):3806-13. PubMed ID: 15897580
[TBL] [Abstract][Full Text] [Related]
14. Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors.
Izquierdo MA; Bowman A; García M; Jodrell D; Martinez M; Pardo B; Gómez J; López-Martin JA; Jimeno J; Germá JR; Smyth JF
Clin Cancer Res; 2008 May; 14(10):3105-12. PubMed ID: 18483378
[TBL] [Abstract][Full Text] [Related]
15. Phase I clinical and pharmacokinetic study of kahalalide F in patients with advanced androgen refractory prostate cancer.
Rademaker-Lakhai JM; Horenblas S; Meinhardt W; Stokvis E; de Reijke TM; Jimeno JM; Lopez-Lazaro L; Lopez Martin JA; Beijnen JH; Schellens JH
Clin Cancer Res; 2005 Mar; 11(5):1854-62. PubMed ID: 15756010
[TBL] [Abstract][Full Text] [Related]
16. Inhalation chemotherapy for macroscopic primary or metastatic lung tumors: proof of principle using dogs with spontaneously occurring tumors as a model.
Hershey AE; Kurzman ID; Forrest LJ; Bohling CA; Stonerook M; Placke ME; Imondi AR; Vail DM
Clin Cancer Res; 1999 Sep; 5(9):2653-9. PubMed ID: 10499645
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer.
Dean E; Jodrell D; Connolly K; Danson S; Jolivet J; Durkin J; Morris S; Jowle D; Ward T; Cummings J; Dickinson G; Aarons L; Lacasse E; Robson L; Dive C; Ranson M
J Clin Oncol; 2009 Apr; 27(10):1660-6. PubMed ID: 19237630
[TBL] [Abstract][Full Text] [Related]
18. Preclinical trial of doxorubicin entrapped in sterically stabilized liposomes in dogs with spontaneously arising malignant tumors.
Vail DM; Kravis LD; Cooley AJ; Chun R; MacEwen EG
Cancer Chemother Pharmacol; 1997; 39(5):410-6. PubMed ID: 9054954
[TBL] [Abstract][Full Text] [Related]
19. Phase I clinical trial with a human major histocompatibility complex nonrestricted cytotoxic T-cell line (TALL-104) in dogs with advanced tumors.
Cesano A; Visonneau S; Jeglum KA; Owen J; Wilkinson K; Carner K; Reese L; Santoli D
Cancer Res; 1996 Jul; 56(13):3021-9. PubMed ID: 8674057
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of intravenous TZT-1027 in patients with advanced or metastatic soft-tissue sarcomas with prior exposure to anthracycline-based chemotherapy.
Patel S; Keohan ML; Saif MW; Rushing D; Baez L; Feit K; DeJager R; Anderson S
Cancer; 2006 Dec; 107(12):2881-7. PubMed ID: 17109446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
